Toronto, Canada (July 5, 2016) – Verity Pharmaceuticals Inc. (“Verity” or the “Company”), a specialty pharmaceutical company announced today the appointment of Mr. Robert Rieder as the Chairman of the Board. Mr. Rieder previously served as President and Chief Executive Officer to ESSA Pharma Inc., which he co-founded, and was the Chief Executive Officer and Executive Chairman of the Board for Cardiome Pharma Corp. from 1998 to 2015.

“We are honored and fortunate that Bob has decided to be the Chairman of the Board. Bob’s extensive experience and expertise will provide invaluable guidance and strategic direction,” said Mr. Howard Glase, Chief Executive Officer.

Mr. Rieder has extensive experience in venture capital and operational management of life science companies and has raised over $250 million of equity financing. Mr. Rieder has held numerous Board seats with biotech and pharma companies. In 2009, he was acknowledged as “Executive of the Year” by Life Sciences BC and in 2007 was named Ernst and Young “Entrepreneur of the Year” for the Medical Products area in the Pacific Region. He holds an MBA from the University of Western Ontario and a BSc degree in Chemical Engineering from the University of British Columbia.

Contact Information:

Howard Glase
General Manager and Chief Executive Officer
Email: publicrelations@veritypharma.com

About Verity Pharmaceuticals Inc.

Verity Pharmaceuticals Inc. is a Canadian owned and operated specialty pharmaceutical company dedicated to providing access to pharmaceutical products which have been withdrawn from the Canadian market or are in short-drug supply. Verity is currently in negotiations to secure eight (8) in-licensing agreements. By working with innovative international pharmaceutical organizations, as well as a highly qualified team of physicians, executives and investors, Verity Pharmaceuticals aims to ensure a predictable high-quality supply of products for the Canadian market.

Forward-Looking Statement

Some of the statements made constitute forward-looking statements as per the Ontario Securities Commission. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance and achievements of Verity Pharmaceuticals Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are often, but not always, identified by words such as ‘believes’, ‘may’, ‘likely’, ‘plans’ or similar words.